Attached files
| file | filename |
|---|---|
| EX-99.1 - Protagenic Therapeutics, Inc.\new | v195866_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): August 31, 2010
ATRINSIC,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-12555
|
06-1390025
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
469
7th
Avenue, 10th Floor,
New York, NY 10018
(Address
of Principal Executive Offices/Zip Code)
(212)
716-1977
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions ( see
General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
Other
Events.
|
On September 2, 2010, Atrinsic, Inc.
(the “Company”) announced that on August 31, 2010 a Nasdaq Hearings Panel
granted the Company’s request for an extension of time, as permitted under
Nasdaq’s Listing Rules, to comply with the $1.00 per share minimum bid price
requirement for continued listing on The Nasdaq Stock Market. The
Company issued a press release in relation to this matter, a copy of which is
being furnished as Exhibit 99.1 to this report and is incorporated herein by
reference.
The
following exhibit is filed herewith:
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
release issued by Atrinsic, Inc., dated September 2,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Atrinsic,
Inc.
|
|||
|
Date:
September 2, 2010
|
By:
|
/s/ Thomas Plotts | |
|
Thomas
Plotts
|
|||
| Chief Financial Officer | |||
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
release issued by Atrinsic, Inc., dated September 2,
2010.
|